Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study-Reference-Cited by-同舟云学术

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

Published:2018-10-11 Issue:1 Volume:68 Page:97-107
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Pistillo Maria Pia^ORCID, ,Fontana Vincenzo,Morabito Anna,Dozin Beatrice,Laurent Stefania,Carosio Roberta,Banelli Barbara,Ferrero Francesca,Spano Laura,Tanda Enrica,Ferrucci Pier Francesco,Martinoli Chiara,Cocorocchio Emilia,Guida Michele,Tommasi Stefania,De Galitiis Federica,Pagani Elena,Antonini Cappellini Gian Carlo,Marchetti Paolo,Quaglino Pietro,Fava Paolo,Osella-Abate Simona,Ascierto Paolo Antonio,Capone Mariaelena,Simeone Ester,Romani Massimo,Spagnolo Francesco,Queirolo Paola

Funder

Italian Minister of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2258-1/fulltext.html

Reference45 articles.

1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

2. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526

3. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al (2015) Pooled analysis of long-term survival data from Phase II and Phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889–1894